Evidence map›Paper›PMID 30938435›Full record

ArticleThe Journal of infectious diseases2019

Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults With Incident HIV-1 Infection.

Matt A Price, Wasima Rida, William Kilembe, Etienne Karita, Mubiana Inambao, Eugene Ruzagira, Anatoli Kamali, Eduard J Sanders, Omu Anzala, Eric Hunter and 18 more

Erratum issuedAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. The HIV Reservoir and Immune Landscape Across the Life Course of Women: Implications for Cure Strategies.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  3. Development and genomic characterization of a diverse HIV-1 variant reference panel for nucleic acid-based testing.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Drug resistance in children and adolescents with HIV in Panama.The Journal of antimicrobial chemotherapy · 2023
    Article
  10. Sex Differences in HIV Infection.Current topics in microbiology and immunology · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. HIV-1Viruses · 2021
    Article
  19. Hidden in plain sight: sex and gender in global pandemics.Current opinion in HIV and AIDS · 2021
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Matt A PriceInternational AIDS Vaccine Initiative, New York, New York.
Wasima Rida
William KilembeRwanda Zambia HIV Research Group, Lusaka and Ndola.
Etienne KaritaRwanda Zambia HIV Research Group, Lusaka and Ndola.
Mubiana InambaoRwanda Zambia HIV Research Group, Lusaka and Ndola.
Eugene RuzagiraMRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
Anatoli KamaliInternational AIDS Vaccine Initiative, New York, New York.
Eduard J SandersKenyan Medical Research Institute-Wellcome Trust, Kilifi, Nairobi, Kenya.
Omu AnzalaKAVI Institute of Clinical Research, Nairobi, Kenya.
Eric HunterRwanda Zambia HIV Research Group, Lusaka and Ndola.
Susan AllenRwanda Zambia HIV Research Group, Lusaka and Ndola.
Vinodh A EdwardDepartment of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut.
Kristin M WallRwanda Zambia HIV Research Group, Lusaka and Ndola.
Jianming TangDepartment of Medicine, University of Alabama-Birmingham.
Patricia E FastInternational AIDS Vaccine Initiative, New York, New York.
Pontiano KaleebuMRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
Shabir LakhiRwanda Zambia HIV Research Group, Lusaka and Ndola.
Gaudensia MutuaKAVI Institute of Clinical Research, Nairobi, Kenya.
Linda Gail BekkerDesmond Tutu HIV Foundation, Cape Town, South Africa.
Ggayi Abu-BakerMRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
Amanda TichacekRwanda Zambia HIV Research Group, Lusaka and Ndola.
Paramesh ChettyInternational AIDS Vaccine Initiative, New York, New York.
Mary H LatkaThe Aurum Institute, South Africa.
Pholo MaenetjeThe Aurum Institute, South Africa.
Heeran MakkanThe Aurum Institute, South Africa.
Freddie KibengoMRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
Fran PriddyInternational AIDS Vaccine Initiative, New York, New York.
Jill GilmourInternational AIDS Vaccine Initiative Human Immunology Laboratory, London, United Kingdom.

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
CTL and HIV Polymorphisms in Heterosexual TransmissionR01AI064060 · NIAID · EMORY UNIVERSITY · PI GOEPFERT, PAUL A., HUNTER, ERIC · 2005 to 2019
$21.7M
Virologic Correlates of Heterosexual TransmissionR01AI051231 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ALLEN, TODD M, HUNTER, ERIC · 2002 to 2022
$9.9M
Medical Research Council MC_UU_00027/1NIAID NIH HHS R01 AI051231NIAID NIH HHS R01 AI064060NIH HHS P51 OD011132
6 · The paper itself

Abstract

Few human immunodeficiency virus (HIV)-infected persons can maintain low viral levels without therapeutic intervention. We evaluate predictors of spontaneous control of the viral load (hereafter, "viral control") in a prospective cohort of African adults shortly after HIV infection. Viral control was defined as ≥2 consecutively measured viral loads (VLs) of ≤10 000 copies/mL after the estimated date of infection, followed by at least 4 subsequent measurements for which the VL in at least 75% was ≤10 000 copies/mL in the absence of ART. Multivariable logistic regression characterized predictors of viral control. Of 590 eligible volunteers, 107 (18.1%) experienced viral control, of whom 25 (4.2%) maintained a VL of 51-2000 copies/mL, and 5 (0.8%) sustained a VL of ≤50 copies/mL. The median ART-free follow-up time was 3.3 years (range, 0.3-9.7 years). Factors independently associated with control were HIV-1 subtype A (reference, subtype C; adjusted odds ratio [aOR], 2.1 [95% confidence interval {CI}, 1.3-3.5]), female sex (reference, male sex; aOR, 1.8 [95% CI, 1.1-2.8]), and having HLA class I variant allele B*57 (reference, not having this allele; aOR, 1.9 [95% CI, 1.0-3.6]) in a multivariable model that also controlled for age at the time of infection and baseline CD4+ T-cell count. We observed strong associations between infecting HIV-1 subtype, HLA type, and sex on viral control in this cohort. HIV-1 subtype is important to consider when testing and designing new therapeutic and prevention technologies, including vaccines.

Indexed as

AfricaAIDSepidemiologyHIVHIV subtype

Identifiers

PMID30938435
PMCPMC6603968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.